Abstract：
Vaccines targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been pivotal in curtailing the spread of infection. Health care workers, as frontline responders, were among the first to receive vaccination to mitigate coronavirus disease in 2019 (COVID-19) transmission. This study aimed to assess the humoral response elicited by mRNA vaccines, specifically measuring antibodies against the spike S1 protein, a marker of immune response. A cohort of 649 health care workers received three doses of mRNA vaccine, with antibody levels evaluated before and after each dose within a 2- to 3-week interval. Participants were stratified into groups based on prior exposure to the virus: those without prior contact (440 individuals) and those with a history of infection (209 individuals). Among the latter, cases of SARS-CoV-2 infection ranged from asymptomatic (92 individuals) to mild symptomatic (117 individuals). Participants with a history of infection exhibited elevated levels of IgG antibodies against the S1 protein prior to vaccination. Notably, both immunoglobulin IgA class (IgA) and immunoglobulin IgG class (IgG) antibody responses increased significantly post-vaccination, peaking after the second dose for IgG and after the third dose for IgA. Interestingly, the immune response to the vaccine did not vary significantly based on the symptomatic or asymptomatic nature of prior infection. Furthermore, the study findings indicate that completion of the vaccination regimen led to sustained antibody production lasting between 6 months and 9 months. This study underscores the robust and enduring humoral response elicited by mRNA vaccines, particularly among health care workers, irrespective of prior SARS-CoV-2 exposure.
摘要：
针对严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）的疫苗在减少感染传播方面至关重要。卫生保健工作者,作为前线响应者，是2019年首批接受疫苗接种以减轻冠状病毒疾病(COVID-19)传播的国家之一。本研究旨在评估mRNA疫苗引起的体液反应，专门测量抗尖峰S1蛋白的抗体，免疫反应的标志.649名医护人员接受了三剂mRNA疫苗，在2至3周的间隔内评估每个剂量之前和之后的抗体水平。参与者根据先前暴露于病毒的情况分为几组：没有先前接触过的人（440人）和有感染史的人（209人）。在后者中,SARS-CoV-2感染的病例范围从无症状（92例）到轻度症状（117例）。有感染史的参与者在接种前表现出针对S1蛋白的IgG抗体水平升高。值得注意的是,免疫球蛋白IgA类(IgA)和免疫球蛋白IgG类(IgG)抗体应答在接种后显著增加,在IgG的第二剂量和IgA的第三剂量之后达到峰值。有趣的是,根据以前感染的症状或无症状性质,对疫苗的免疫应答没有显著差异.此外，研究结果表明，完成疫苗接种方案导致持续6个月至9个月的抗体产生。这项研究强调了mRNA疫苗引起的强大而持久的体液反应，特别是在医护人员中，与之前的SARS-CoV-2接触无关。
